· OR legislature · 2025R1

Relating to medical treatments with investigational products.

Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration. Provides protections, including a waiver of liability, for health care practitioners,…

Sponsor

Ben Bowman (D-OR)

Introduced

2025-02-27

Policy area

Health

Latest action

In committee upon adjournment.